RAAS: The Body’s Blood Pressure Control System

What Triggers RAAS?

The kidneys detect reduced perfusion or sodium at the juxtaglomerular apparatus. In response, they release renin into circulation. Renin cleaves angiotensinogen, a liver-derived protein, into angiotensin I. Angiotensin I travels to the lungs, where ACE converts it into angiotensin II. This conversion activates the system’s potent downstream effects.

What Does Angiotensin II Do?

Angiotensin II causes intense vasoconstriction, especially in arterioles. It increases systemic resistance and raises blood pressure. It also stimulates the hypothalamus to increase thirst. Simultaneously, it signals the posterior pituitary to release antidiuretic hormone (ADH). These responses promote fluid retention and restore circulatory volume.

Aldosterone’s Role

Angiotensin II also targets the adrenal cortex, stimulating aldosterone release. Aldosterone acts on the distal tubules and collecting ducts of the kidney. It increases sodium and water reabsorption while enhancing potassium excretion. This boosts intravascular volume and supports blood pressure recovery.

Why It Matters Clinically

The RAAS response protects against acute hypovolemia or hypotension. But chronic activation causes disease. It drives essential hypertension and worsens systolic heart failure. It also accelerates kidney fibrosis and proteinuria. Left unchecked, RAAS overactivity contributes to widespread vascular and organ damage.

Medical Treatments That Target RAAS

Hypertension specialists use multiple agents to block RAAS. ACE inhibitors block angiotensin II formation in the lungs. ARBs prevent angiotensin II from binding to its AT1 receptor. Aldosterone antagonists block mineralocorticoid receptors in the kidney. These therapies reduce morbidity and mortality in cardiovascular and renal patients.

Monitoring During Therapy

RAAS blockers can raise potassium and reduce glomerular filtration. Endocrinologists monitor electrolytes and kidney function closely. Benefits still outweigh risks, especially in diabetic nephropathy, heart failure and post-myocardial infarction care.

Summary

RAAS integrates renal, liver, pulmonary, pituitary, adrenal, and neuroendocrine signals to defend blood pressure. Chronic overdrive causes harm. Blocking this pathway remains essential in treating hypertension, heart failure, and chronic kidney disease.